Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells

Race Oncology Limited (“Race”) is pleased to share results from recent preclinical work performed under contract at Oncolines (Netherlands).

In these studies, bisantrene was screened for anti-cancer activity in a broad panel of 143 human cancer cell lines, representing 15 distinct cancer types, alone and in combination with doxorubicin, an anthracycline chemotherapeutic that is one of the most widely used anti-cancer drugs.